Related Experiment Video
Updated: May 21, 2026

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
Published on: September 15, 2023
UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway
Zhou Zhou1, Yuhang Chen2,3, Ping Li1
1Oncology Department of Integrated Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, He Fei, Anhui, China.
Abstract:
UBE2C, a key member of the ubiquitin-proteasome system, is overexpressed in various malignant tumors and correlates with poor prognosis. Our findings reveal that UBE2C expression is elevated in both pancreatic cancer cell lines and tissues compared to normal pancreatic cells and tissues, with this aberrant expression linked to a poor prognosis. Knockdown of UBE2C expression reduces pancreatic cancer cell proliferation, migration, and invasion, while significantly decreasing the phosphorylation of the PI3K/AKT/mTOR signaling pathway. Administration of the pathway activator SC79 reverses the inhibitory effects of UBE2C knockdown on the PI3K/AKT/mTOR pathway, restoring the proliferation, migration, and invasion of pancreatic cancer cells. These results suggest that UBE2C promotes pancreatic cancer progression via the PI3K/AKT/mTOR signaling pathway. Thus, UBE2C serves as a potential biomarker for the early detection and diagnosis of pancreatic cancer and may represent a promising therapeutic target.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
Acute Pancreatitis II: Pathophysiology
Canonical Wnt Signaling Pathway

